Source: LinkedIn
  • Rubicon Organics (ROMJ) has signed a supply agreement with Medical Cannabis by Shoppers Drug Mart Inc. 
  • The agreement includes Simply Bare™ Organic hash, as well as both Wildflower CBD Relief Sticks and Wildflower CBD Cool Sticks
  • The supply agreement with Shoppers will grow Rubicon’s portfolio of brands in the Canadian medical cannabis channel
  • Rubicon cultivates, processes and sells organically certified, sustainably produced, premium cannabis products
  • Rubicon Organics Inc. (ROMJ) opened trading at C$2.35 per share

Rubicon Organics (ROMJ) has signed a cannabis products supplier agreement with Medical Cannabis by Shoppers Drug Mart Inc. 

The supply agreement with Shoppers includes Simply Bare™ Organic hash, as well as both Wildflower CBD Relief Sticks and Wildflower CBD Cool Sticks in both 30g and 73g product formats. These products will be made available on the Medical Cannabis by Shoppers™ platform.

Rubicon Chief Executive Officer Jesse McConnell commented on the agreement.

“Rubicon Organics has made great strides in consistently increasing its distribution across Canada and this supply agreement significantly advances the presence of our portfolio of brands in the Canadian medical cannabis channel. We have a deep product innovation portfolio that is equally applicable to the medical and recreational cannabis markets, and we expect to solidify our leadership position in the Canadian premium and organic cannabis segments as we roll-out our innovation across the country in the coming months.”

Rubicon Organics Inc. is becoming the global brand leader in organic cannabis products. Through its wholly-owned subsidiary Rubicon Holdings Corp, the company cultivates, processes and sells organically certified, sustainably produced, premium cannabis products from its state-of-the-art hybrid greenhouse in BC.

Rubicon Organics Inc. (ROMJ) opened trading at C$2.35 per share.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.